- Home
- News
- latamerica
- bone marrow cell
Bone Marrow Cell Articles & Analysis
14 news found
Myelodysplastic syndromes are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. For roughly 30% of the patients diagnosed with MDS, this type of bone marrow failure syndrome will progress to AML, which is often fatal. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an ...
Data from 15 treated patients to be presented are expected to provide initial evidence of successful engraftment of Temferon-derived cells and of on-target biological activity in patients with uMGMT-GBM. One month after administration of the highest tested dose so far, the hematopoietic system of Temferon-treated patients was composed of up to 30% gene modified ...
” The article, titled “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” details the study findings on Longeveron’s lead investigational product, Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) product, given to patients with mild Alzheimer’s ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. ...
We are delighted to partner with the site leadership teams in Canada and the United States to further the development of this promising treatment option for their patients with ischemic heart failure. ” About the CardiAMP Cell Therapy Program CardiAMP cell therapy uses a patient’s own (autologous) bone marrow ...
In fact, we believe that the trial now has the largest enrollment of any trial of intramyocardial bone marrow mononuclear cells performed in ischemic heart failure to date,” said BioCardia CEO Peter Altman, Ph.D. ...
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. ...
This facility is being built out to support the manufacturing of BioCardia’s cell and device products and product candidates across the Company’s therapeutic pipeline. The new facility is expected to provide manufacturing capabilities across BioCardia’s portfolio, including its CardiAMP Cell Therapy Systems, NK1R+ mesenchymal stem ...
Also, this conference was a highlight such as CD80-CD28 mechanism, NK cell therapy, bone marrow-derived immune cell and GI-101 is centered among the various immune checkpoint ...
The first patient was treated with the investigational CardiAMP autologous cell therapy at the University of Wisconsin in Madison, by Interventional Cardiologist and Associate Professor of Medicine Amish Raval, M.D., supported by Peiman Hematti, M.D., Bone Marrow Transplantation Hematologist and Professor of Medicine. ...
Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its study entitled “A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic ...
For example, researchers at the Gladstone Institutes in San Francisco received $5.9 million to develop a new way to help the more than five million Americans battling Alzheimer’s disease. They want to generate brain cells to replace those damaged by Alzheimer’s, using induced pluripotent stem cells (iPSCs) – an adult cell that ...
Human umbilical cord blood provides a rich source of hematopoietic (blood) multipotent stem cells that can differentiate and give rise to all of the blood cell types. ...